Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
254 results about "Host disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Definition Graft-vs.-host disease is an immune attack on the recipient by cells from a donor. The main problem with transplanting organs and tissues is that the recipient host does not recognize the new tissue as its own.
Substituted Benzoazepines As Toll-Like Receptor Modulators
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and / or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.
Owner:ARRAY BIOPHARMA +1
Substituted benzoazepines as toll-like receptor modulators
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and / or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
Owner:ARRAY BIOPHARMA
Substituted benzoazepines as toll-like receptor modulators
ActiveUS20110118235A1Efficient modulationAntibacterial agentsBiocideTLR8Graft versus host disease induction
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and / or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
Owner:ARRAY BIOPHARMA +1
Compound capable of binding s1p receptor and pharmaceutical use thereof
InactiveUS20070167425A1Enhance pharmacological effectsLittle side effectsBiocideOrganic chemistryAutoimmune conditionHydrogen atom
A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and / or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like. wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.
Owner:ONO PHARMA CO LTD
Methods for prevention and treatment of septic shock
Berberine or pharmaceutically acceptable salts thereof either alone or in combination with cyclosporin can be used to treat or prevent graft vs. host disease. Berberine or pharmaceutically acceptable salts thereof can also be used to treat or prevent septic shock syndrome.
Owner:NATIONAL INSTUTUTE OF IMMUNOLOGY
Inhibiting B cell activation with soluble CD40 or fusion proteins thereof
The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40 / immunoglobulin fusion protein or antibody specific for gp39 on T cells was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease, including graft-versus-host disease and rheumatoid arthritis.
Owner:BRISTOL MYERS SQUIBB CO +1
Il-21 antagonists
InactiveUS20070122413A1Increasing in vivo serum half-lifeModulate antibody responseNervous disorderAntibody mimetics/scaffoldsAutoimmune conditionAutoimmune disease
Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
Owner:ZYMOGENETICS INC
Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
InactiveUS20020127208A1Effective in treating and preventing infectionReduce capacityBiocideGenetic material ingredientsAllogeneic cellHematopoietic cell
The present invention provides a method of transplanting hematopoietic cells between genetically unrelated individuals, comprising administering to the recipient, in combination with the administration of the hematopoietic cells, an amount of mononuclear cells which are treated so as to substantially reduce their ability to cause graft versus host disease while they retain their ability to proliferate in the recipient. The treated mononuclear cells can facilitate engraftment of hematopoietic cells when transplanted in combination with hematopoietic cells, treat or prevent infections, and treat cancer.
Owner:EMORY UNIVERSITY
Method of producing FR901228
InactiveUS7396665B2Increase productionAntibacterial agentsMicroorganism based processesIMMUNE SUPPRESSANTSDipeptide
Owner:ASTELLAS PHARMA INC
Purging of cells using viruses
InactiveUS20020037543A1Preventing graft-versus-host diseasesHigh selectivityNervous disorderPeptide/protein ingredientsAutoimmune conditionGraft versus host disease induction
The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.
Owner:PRO VIRUS
Pharmaceutical compositions and dosage forms of thalidomide
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
Owner:CELGENE CORP
Antibodies that specifically bind to TL5
The present invention relates to antibodies and related molecules that specifically bind to TL5. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including autoimmune disease, rheumatoid arthritis, graft rejection, graft vs. host disease, and lymphadenopathy. The invention also relates to nucleic acid molecules encoding anti-TL5 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer as well as immune system diseases and disorders including autoimmune disease, rheumatoid arthritis, graft rejection, graft vs. host disease, and lymphadenopathy, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to TL5.
Owner:HUMAN GENOME SCI INC
Antibodies directed against icos for treating graft-versus-host disease
ActiveUS20150239978A1Induces and survivalSimple processImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesHost disease
The invention relates to a specific antibody directed against, for use for treating graft versus host disease.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Methods for identifying compounds that bind to HLA molecules and use of such compounds as HLA-agonists or antagonists
InactiveUS20020042423A1Minimize interactionEasy to changeBiocideNervous disorderAutoimmune diseaseAgonist
A novel method for identifying compounds which bind HLA molecules and which can be used as HLA agonists or antagonists is provided. These compounds are useful especially in the treatment of autoimmune diseases, transplantation, graft-vs-host disease, and more particularly multiple sclerosis.
Owner:GEORGETOWN UNIV
Deuterated rapamycin compounds, method and uses thereof
InactiveUS6939878B2Reduce oxidation rateReduce formationBiocideOrganic chemistryAutoimmune diseaseHost disease
The synthesis of deuterated analogues of rapamycin is disclosed together with a method for use for inducing immunosupression and in the treatment of transplantation rejection, graft vs host disease, autoimmune diseases, diseases of inflammation leukemia / lymphoma, solid tumors, fungal infections, hyperproliferative vascular disorders. Also described is a method for the synthesis of water soluble deuteratred rapamycin compounds and their use as described above.
Owner:ISOTECHNIKA INC
Treatment of inflammatory, non-infectious, autoimmune, vasculitic, degenerative vascular, host-v-graft diseases, Alzheimers disease, and amyloidosis using mammalian, dsDNA vaccination
The present invention relates generally to compositions and methods using mammalian, dsDNA (Double Stranded Deoxyribonucleic Acid) vaccination for the induction and maintenance of regulator suppressor T cells resulting in suppression of non infectious, and post infectious, inflammatory, allergic, auto-immune, vasculitic, certain degenerative vascular, and graft versus host diseases, with or without the use of IL-10, and with or without the use or TGFβ, with or without the use of anti-IL 6 receptor antibody, anti TNF antibody and or Plasmapheresis, IVIG, Corticosteroids, Methotrexate, Bromocriptine, and or vitamin D analogues.
Owner:LAWLESS OLIVER J
Production Of Polyketides And Other Natural Products
The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. Therefore in aspect the present invention provides 17-desmethylrapamycin and analogues thereof, methods for their production, including recombinant strains, and isolation and uses of the compounds of the invention. In a further aspect the present invention provides for the use of 17-desmethylrapamycin and analogues thereof in the induction or maintenance of immunosuppression, the stimulation of neuronal regeneration or the treatment of cancer, B-cell malignancies, fungal infections, transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation vascular disease and fibrotic diseases, and in the regulation of wound healing.
Owner:BIOTICA TECH
Compound capable of binding S1P receptor and pharmaceutical use thereof
InactiveUS7825109B2Enhance pharmacological effectsBiocideOrganic chemistryAutoimmune conditionS1P Receptor
A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and / or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like.wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.
Owner:ONO PHARMA CO LTD
Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
ActiveUS20090148419A1Improve severityReduce mortalityBiocideMammal material medical ingredientsAllo hsctGraft versus host disease induction
The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation.
Owner:CENT DE INVESTIGACIONES ENERGETICAS MEDIO AMBIENTALLES Y TECNOLOGICAS (C I E M A T) +2
Piperidine derivatives useful as CCR5 antagonists
The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R<1>, R<2>, R<3>, R<9>, R<10>, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
Owner:SCHERING CORP
Methods for treating and preventing gi syndrome and graft versus host disease
ActiveUS20100239572A1Regulate hepatocyte apoptosisProtected hepatocytesAntipyreticAnalgesicsAutoimmune diseaseT lymphocyte
We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
Owner:THE UNIV OF TEXAS SYST +1
Piperidine derivatives useful as CCR5 antagonists
The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R<1>, R<2>, R<3>, R<9>, R<10>, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
Owner:SCHERING CORP
Allogeneic cellular immunotherapy for invasive pulmonary aspergillosis (IPA)
ActiveUS20060115487A1Snake antigen ingredientsVertebrate antigen ingredientsAllogeneic cellGraft versus host disease induction
A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion.
Owner:MIRROR BIOLOGICS INC +1
Aminocarboxylic acid derivative and medicinal use thereof
InactiveUS20090275554A1Easy to separateReduce side effectsBiocideSenses disorderAutoimmune conditionS1P Receptor
The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and / or EDG-8) and is useful for preventing and / or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like.wherein all symbols are described in the specification.
Owner:ONO PHARMA CO LTD
Methods of enriching and using regulatory t cells
Disclosed are methods of isolating and using a population of FOXP3+ regulatory T cells in a variety of preventative and therapeutic approaches to autoimmune diseases, graft-versus-host disease and transplant rejection.
Owner:UNITED STATES OF AMERICA
Antibodies that specifically bind to TL5
InactiveUS7541441B2Animal cellsIn-vivo radioactive preparationsAutoimmune diseaseReactive lymphadenopathy
Owner:HUMAN GENOME SCI INC
Sulfonyl urea derivatives and their use in control of interleukin-1 activity
A compound of formula (I) wherein R<1> and R<2> are as defined in the description, R<2> being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and / or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.
Owner:PFIZER INC
Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders
The present invention provides conformationally-defined macrocyclic compounds that bind to and / or are functional modulators of the motilin receptor including subtypes, isoforms and / or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and / or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.
Owner:OCERA THERAPEUTICS INC
Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
Owner:SHENZHEN HIGHTIDE BIOPHARM
Anti-CD26 antibodies and uses thereof
ActiveUS9376498B2Engraftment can be facilitatedImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAplastic bone marrowIntestinal GVHD
Owner:ADIENNE SA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com